Immortagen

Curated by Signal

AI-based NGS solutions for cancer diagnostics

Overview

Immortagen develops AI-based NGS solutions for cancer diagnostics. Their proprietary algorithms use artificial intelligence to analyze next generation sequencing data to identify risk of cancer recurrence and driver mutations in tumors. First application is gynecological cancers. Clients will include clinical diagnostic companies and biopharmaceutical companies that will use these algorithms for intelligent clinical trial design.

Key facts

Founded: 2014
Headquarters: Coralville, United States
Stage: Sign up to view
Industry: Health Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

First Stop Health
Online and on-call health concierge
Health TechnologyChicago, United States
LowerMyRx
Mobile app that enables users to avail discounted drug prices sold by various online pharmacies
Health TechnologyMount Laurel Township, United States
Nutrigene
Manufactures consumer device to dispense vitamin drink from pods
Health TechnologyMountain View, United States

About Immortagen

What does Immortagen do?

Immortagen develops AI-based NGS solutions for cancer diagnostics.

Where is Immortagen headquartered?

Immortagen is headquartered in Coralville, United States.

When was Immortagen founded?

Immortagen was founded in 2014.

Which sector is Immortagen in?

Immortagen operates in Health Technology.

Who are Immortagen's competitors?

Companies similar to Immortagen include First Stop Health, LowerMyRx, and Nutrigene.